Omthera asserts Epanova superiority but US filing delayed to next year
This article was originally published in Scrip
Executive Summary
Omthera Pharmaceuticals is determined to show that Epanova, its free fatty acid formulation of omega-3 that contains both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is superior to Amarin's recently approved ethyl ester omega-3 Vascepa (icosapent ethyl).